(S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetic acid, 97%, 25g

2-(4-Hydroxyphenyl)-N-methylacetamide, 97%, 25g

Di-tert-butyl 4-bromopyrazolidine-1,2-dicarboxylate, 97%, 250mg

4-(4-Chloro-phenylsulfanylmethyl)-piperidine hydrochloride, 95.0%, 250mg

(S)-(+)-2,2-Dimethyl-1,3-dioxolane-4-ylmethyl p-toluenesulfonate, 98.0%, 10g

2-(Pyrrolidin-2-yl)acetic acid, 95.0%, 250mg

6-Methoxy-1H-indazole-3-carboxylic acid, 95.0%, 250mg

(2R,4R)-4-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-1,2-PYRROLIDINEDICARBOXYLIC ACID 2-METHYL 1-(PHENYLMETHYL) ESTER, 95.0%, 1g

5-ACETYLTHIOPHENE-2-CARBOXAMIDE, 95%, 100mg

1-(3-(Benzyloxy)isoxazol-5-yl)-2-bromoethanone, 97.0%, 250mg

2-(6-Chloropyridin-3-yl)ethan-1-amine, 98%, 100mg

Microliter syringe GASTIGHT® series 1700 Point type 3, 500 µl, 1750 RNR, 1 piece

Ethyl 4-(4-bromophenyl)-2,4-dioxobutanoate, 95.0%, 5g